[When two do the same, it is not the same. Requirements for development and quality of biosimilars].

Suppr

超能文献

作者信息

Rais Isam

出版信息

Pharm Unserer Zeit. 2012 Nov;41(6):453-60. doi: 10.1002/pauz.201200491.

DOI:10.1002/pauz.201200491

PMID:23362548

Abstract

摘要

相似文献

[When two do the same, it is not the same. Requirements for development and quality of biosimilars].

Pharm Unserer Zeit. 2012 Nov;41(6):453-60. doi: 10.1002/pauz.201200491.

J Biopharm Stat. 2014;24(6):1154-64. doi: 10.1080/10543406.2014.941994.

Precision and robustness of 2D-NMR for structure assessment of filgrastim biosimilars.

Nat Biotechnol. 2016 Feb;34(2):139-41. doi: 10.1038/nbt.3474.

Differences in bioanalytical method validation for biologically derived macromolecules (biosimilars) compared with small molecules (generics).

Bioanalysis. 2011 Jul;3(14):1551-3. doi: 10.4155/bio.11.129.

Analytic characterization of biosimilars.

Am J Health Syst Pharm. 2017 Apr 15;74(8):568-579. doi: 10.2146/ajhp150971.

Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study.

MAbs. 2018 Jan;10(1):143-158. doi: 10.1080/19420862.2017.1402996. Epub 2017 Dec 7.

Einstein (Sao Paulo). 2019 Feb 25;17(1):eED4836. doi: 10.31744/einstein_journal/2019ED4836.

Biosimilar medicines - Review.

Int J Risk Saf Med. 2016 Mar 16;28(1):45-60. doi: 10.3233/JRS-160672.

An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin.

BioDrugs. 2015 Aug;29(4):285-300. doi: 10.1007/s40259-015-0136-3.

Biosimilar regulation in the EU.

Expert Rev Clin Pharmacol. 2015;8(5):649-59. doi: 10.1586/17512433.2015.1071188.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

[When two do the same, it is not the same. Requirements for development and quality of biosimilars].

Pharm Unserer Zeit. 2012 Nov;41(6):453-60. doi: 10.1002/pauz.201200491.

J Biopharm Stat. 2014;24(6):1154-64. doi: 10.1080/10543406.2014.941994.

Precision and robustness of 2D-NMR for structure assessment of filgrastim biosimilars.

Nat Biotechnol. 2016 Feb;34(2):139-41. doi: 10.1038/nbt.3474.

Differences in bioanalytical method validation for biologically derived macromolecules (biosimilars) compared with small molecules (generics).

Bioanalysis. 2011 Jul;3(14):1551-3. doi: 10.4155/bio.11.129.

Analytic characterization of biosimilars.

Am J Health Syst Pharm. 2017 Apr 15;74(8):568-579. doi: 10.2146/ajhp150971.

Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study.

MAbs. 2018 Jan;10(1):143-158. doi: 10.1080/19420862.2017.1402996. Epub 2017 Dec 7.

Einstein (Sao Paulo). 2019 Feb 25;17(1):eED4836. doi: 10.31744/einstein_journal/2019ED4836.

Biosimilar medicines - Review.

Int J Risk Saf Med. 2016 Mar 16;28(1):45-60. doi: 10.3233/JRS-160672.

An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin.

BioDrugs. 2015 Aug;29(4):285-300. doi: 10.1007/s40259-015-0136-3.

Biosimilar regulation in the EU.

Expert Rev Clin Pharmacol. 2015;8(5):649-59. doi: 10.1586/17512433.2015.1071188.